GSK-2881078 Powder is an experimental SARM (selective androgen receptor modulator). Like other SARMs, GSK2881078 is designed to provide the muscle-building and bone-strengthening benefits of anabolic steroids while minimizing the side effects. The following is an overview of what is known about GSK2881078, which benefits muscular dystrophy and osteoporosis through its selective targeting and anabolic effects. GSK2881078 has been in early clinical trials to evaluate its safety, tolerability, pharmacokinetics (how a drug is absorbed, distributed, metabolized, and excreted), and pharmacodynamics (the effects of a drug on the body). Results of the studies Preliminary studies show that the drug has promise in muscle growth and bone health. Still, more extensive studies are needed to understand its efficacy and safety fully. GSK2881078 represents a potential advancement in the development of SARMs.
Shaanxi Medibridge Biotech Co., Ltd. focuses on the supply of pharmaceutical raw materials and research-use compounds. We support customers with stable quality, clear specification communication, flexible packaging options, and document-related support for different project stages.
Androgen Receptor–Mediated Transcriptional Regulation
GSK-2881078 primarily acts through the androgen receptor (AR). A comparative study demonstrated androgenic functional activity using a yeast androgen screen and a reporter gene assay in human PC3(AR)₂ cells.
AR is a nuclear receptor. Mechanistic investigations can examine ligand binding, receptor nuclear localization, androgen response element–dependent transcription, and downstream cellular responses.
Mechanistic validation should combine AR reporter activity, receptor expression, cell viability, and receptor blockade or knockdown experiments to establish AR dependence.
Interpreting the SARM Classification
Selective androgen receptor modulators are developed to achieve some separation between anabolic effects in target tissues, such as skeletal muscle, and androgenic effects in other tissues. This selectivity must be demonstrated through comparative functional measurements; AR binding alone cannot establish it.
Three aspects should be distinguished when studying GSK-2881078:
- Target selectivity: Activity at AR compared with other receptors.
- Tissue selectivity: Differences in responses between tissues at comparable exposure.
- Functional selectivity: Whether changes in body composition, strength, and other physiological outcomes occur together.
Comparative studies should measure exposure–response relationships across relevant models while monitoring actual compound concentrations and viability.
Skeletal Muscle and Lean Body Mass Research
A study in healthy older men and women reported dose-dependent increases in lean body mass with GSK-2881078, with evidence of greater sensitivity in women for this endpoint.
These findings support its value in body-composition research. However, increased lean body mass does not automatically establish improved strength or physical performance. Lean mass measured by dual-energy X-ray absorptiometry (DXA) should also not be equated directly with newly synthesized contractile muscle protein.
COPD-Associated Muscle Weakness and Human Functional Research
A phase IIa randomized, double-blind, placebo-controlled trial enrolled 47 postmenopausal women and 50 men with COPD. The study lasted 13 weeks and included a concurrent home-based strength-training and physical-activity program. Outcomes included leg strength, lean body mass, and functional measures.
The male result supported an additional strength-improvement signal on this measure. The female confidence interval included zero, leaving the corresponding benefit uncertain.
Interpretation should retain the study's context: participants had COPD, both groups received exercise support, and observation lasted 13 weeks.
Pharmacokinetics, Exposure, and Drug Interaction Research
The first-in-human study investigated GSK-2881078 pharmacokinetics, tolerability, and pharmacodynamic responses. For research involving the powder, a central question is how measured exposure relates to receptor activity and functional outcomes.
A publicly available clinical trial protocol reported that coadministration with the strong CYP3A4 inhibitor itraconazole increased GSK-2881078 AUC by approximately 60%, while Cmax decreased by approximately 21%. These findings illustrate the need to evaluate overall exposure and peak concentration separately. They do not establish CYP3A4 as the sole clearance pathway.
Safety: Hepatic, Lipid, and Endocrine Measurements
Published human studies identified safety findings that warrant careful evaluation. The COPD trial reported reversible reductions in HDL cholesterol and transient elevations in hepatic transaminases. An earlier study in healthy participants also reported ALT elevations.
Research in healthy older participants additionally reported reversible reductions in testosterone levels in men. Endocrine assessment should therefore consider total testosterone, free testosterone, sex hormone–binding globulin (SHBG), LH, and FSH together. Total testosterone changes alone cannot fully characterize effects on the reproductive endocrine axis.
Research Application Positioning
Evidence-supported research applications for GSK-2881078 include AR functional characterization, comparative pharmacology, relationships between lean mass and strength, and muscle dysfunction associated with chronic disease. It can also support investigations of exposure-related hepatic, lipid, and endocrine responses.
Its research value lies in the availability of receptor-based experiments and human studies that can inform experimental design.
FAQ
What is the primary research application of GSK-2881078?
GSK-2881078 is a selective androgen receptor modulator (SARM) primarily used to investigate skeletal muscle metabolism and muscle wasting conditions in vitro and in vivo.
How should stock solutions be prepared for cellular or biochemical assays?
Reconstitute the powder in high-purity DMSO to prepare concentrated stock solutions, which should be diluted immediately prior to experimental use.
Does GSK-2881078 exhibit high aqueous solubility?
It has very low aqueous solubility, making organic solvents like DMSO or ethanol essential for initial dissolution.
What safety precautions should researchers take when handling the compound?
Standard laboratory personal protective equipment (PPE) including gloves, a lab coat, and a mask should be used to avoid direct inhalation or dermal contact.
If you are looking for a high-quality GSK-2881078 Powder manufacturer with whom you can establish a long-term, stable partnership, then Shaanxi Medibridge Biotech Co., Ltd. would be your best business partner. Don't hesitate to contact us at hi@medibridgeapi.com.
Hot Tags: gsk-2881078 powder, China gsk-2881078 powder manufacturers, suppliers, factory, cilostazol pharmaceutical material, cobicistat active compound powder, dicyclanil research compound, Heparin Sodium Powder, picamilon api, prilocaine injectable solution ingredient
